Loading clinical trials...
Loading clinical trials...
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study of CK-2127107 in Two Ascending Dose Cohorts of Patients With Spinal Muscular Atrophy
Conditions
Interventions
Placebo
Reldesemtiv 150 mg
+1 more
Locations
19
United States
UCLA
Los Angeles, California, United States
University of California Irvine
Orange, California, United States
Pediatric Neuromuscular Clinic Stanford University
Palo Alto, California, United States
Children's Hospital Colorado
Aurora, Colorado, United States
Hospital for Special Care
New Britain, Connecticut, United States
Nemours Childrens Hospital
Orlando, Florida, United States
Start Date
January 14, 2016
Primary Completion Date
May 31, 2018
Completion Date
May 31, 2018
Last Updated
August 31, 2020
NCT06321965
NCT07332702
NCT07265232
NCT05824169
NCT06756633
NCT05638750
Lead Sponsor
Cytokinetics
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions